ExCell Bio Warmly Congratulates Qyuns Therapeutics (2509.HK), on Signing a Global Exclusive Licensing Agreement with Roche for QX031N!

On October 28, Qyuns Therapeutics (2509.HK), a partner of ExCell Bio, entered into a global exclusive cooperation and license agreement with F. Hoffmann-La Roche Ltd ("Roche") for QX031N, a long-acting bispecific antibody for autoimmune diseases independently developed by Qyuns Therapeutics (2509.HK).

This agreement grants Roche the global exclusive rights to research, develop, manufacture, register, and commercialize QX031N worldwide. In return,Qyuns Therapeutics (2509.HK) received a one-time, non-refundable, and non-creditable upfront payment of USD 75 million. It is also eligible for up to USD 995 million in milestone payments tied to product development, regulatory approvals, and commercialization, plus tiered royalties on potential future product sales . The drug candidate, QX031N, is a long-acting bispecific antibody targeting TSLP and IL-33, proteins that play important roles in respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma, and it is currently in the preclinical stage .

This deal is a significant "out-licensing" achievement for Qyuns Therapeutics (2509.HK), following its previous agreement with Caldera Therapeutics for another asset, QX030N, in April 2025. It also aligns with Roche's recent pattern of collaborating with Chinese biopharmaceutical companies.

As a long-standing and crucial partner of Qyuns Therapeutics (2509.HK), ExCell Bio extends our warmest congratulations on this significant milestone! We have consistently followed with great interest Qyuns's dedicated efforts in the field of biotherapies for autoimmune and allergic diseases. We look forward to their continued advancement in the development and commercialization of more antibody therapeutics, ultimately benefiting patients worldwide.

ExCell Bio provides global clients with efficient and stable,GMP-grade cell culture media, products that have obtained FDA Drug Master File (DMF) filings. These media solutions streamline the approval process for Investigational New Drug (IND) applications and expedite the transition of innovative therapeutics into clinical stages.